Sudeep Pharma Limited
Sudeep Pharma Limited (SUDEEPPHRM): company summary
The company's business is improving, with annual revenue rising 27.9% and annual net profit growing 25.4%.
Sudeep Pharma Limited (SUDEEPPHRM) is a small-cap Chemicals company valued at ₹11,301 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Sudeep Pharma Limited last traded at ₹1,020, modestly up 1.18% on the day.
- Recent developments
- 2026-09-04: Sudeep Pharma's stock hit a 52-week high, with the company among eight commodities stocks that surged to fresh highs in the past month, with gains ranging from 14% to 53%.
- Financial performance
- The company's business is improving, with annual revenue rising 27.9% and annual net profit growing 25.4%. The latest quarter saw revenue and net profit both rise compared to the same quarter a year earlier, with revenue up 26.6% and net profit up 30.9%. However, the net profit margin narrowed slightly to 27.1% from 27.7% in the prior year.
- Valuation multiples
- The stock trades at 65.8 times earnings, 15.50 times book value. It yields 0.1%.
- Things to watch
- The stock is 12.9% below its 52-week high. Domestic institutional holding fell by 2.46 percentage points in the quarter. The net profit margin narrowed by 0.6 percentage points, and the return on equity is 19.6%, which is lower than the return on capital employed of 22.8%.
- Where it stands
- Sudeep Pharma Limited's latest quarter revenue and net profit both rose compared to the same quarter a year earlier, with net profit growing faster. The stock is 12.9% below its 52-week high, and the net profit margin narrowed slightly. The company's return on capital employed is higher than its return on equity.
Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
Price performance
Supported by growth (8.5) and risk (8.5), but held back by valuation (0.0). Growth looks strong at 8.5, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidenceAt a glance
Key highlights
- Profit compounding 39% a year
- Low leverage — D/E 0.17
- Profitable in all of the last 5 years
- Valuation is weak (0.0/10)
- Expensive at 66× earnings
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Chemicals stocks · Pharmaceuticals
Explore Sudeep Pharma Limited’s valuation
Free deep-dive tools · no sign-up
Sudeep Pharma Limited peers in Chemicals
Other Chemicals stocks on the NSE & BSE. See the full Chemicals sector list.
Related tools & concepts
Value Sudeep Pharma Limited with the ratios and calculators DocStoX uses in its analysis.

